Polyclonal Pulmonary Tuberculosis Infections and Risk for Multidrug Resistance, Lima, Peru

Ruvandhi R. Nathavitharana, Cynthia X. Shi, Leonid Chindelevitch, Roger Calderon, Zibiao Zhang, Jerome T. Galea, Carmen Contreras, Rosa Yataco, Leonid Lecca, Mercedes C. Becerra, Megan B. Murray, Ted Cohen

Because within-host Mycobacterium tuberculosis diversity complicates diagnosis and treatment of tuberculosis (TB), we measured diversity prevalence and associated factors among 3,098 pulmonary TB patients in Lima, Peru. The 161 patients with polyclonal infection were more likely than the 115 with clonal or the 2,822 with simple infections to have multidrug-resistant TB.

Within-host heterogeneity of Mycobacterium tuberculosis infection is increasingly recognized as an obstacle for the accurate diagnosis (1) and effective treatment (2) of tuberculosis (TB) and may complicate the control of TB in communities (3). Within-host heterogeneity may arise through 2 mechanisms: 1) by reinfection or simultaneous infection with multiple strains, which results in a polyclonal (mixed) infection, or 2) by accumulation of mutations, which results in clonal heterogeneity (4). The treatment challenge posed by within-host heterogeneity has been most clearly demonstrated for infections with drug-susceptible and drug-resistant variants (5). The relatively high prevalence of multidrug-resistant (MDR) TB in Peru (≈6% among new case-patients and 21% among retreatment case-patients) (6) places increased stress on the healthcare system.

Our main objectives were to estimate the prevalence of within-host M. tuberculosis heterogeneity at the time of treatment initiation in a large cohort of pulmonary TB patients in Peru and to determine if factors measurable at the baseline visit were associated with complex infections (7). To determine whether our insights were sensitive to the method used for distinguishing between classes of heterogeneous infections, we used a newly described method (classifier of tandem repeats [ClassTR]) (8), which uses 24-loci mycobacterial interspersed repetitive units–variable number of tandem repeats (MIRU-VNTR) data to distinguish polyclonal and clonal infections, and we compared these findings with an analysis based on the standard threshold-based approach (9).

The Study
During September 2009–August 2012, we attempted to enroll all adults (>15 years of age) with a diagnosis of incident pulmonary TB from 106 healthcare centers in Lima, Peru; details of the study design have been reported previously (7). We recorded baseline data on demographics, medical history, and results of drug susceptibility testing (DST) for rifampin, isoniazid, streptomycin, ethambutol, and pyrazinamide. We restricted our analysis to pretreatment samples and data from participants with culture-positive TB from whom sufficient mycobacterial DNA could be successfully obtained from the baseline sample to perform MIRU-VNTR typing.

All enrolled index case-patients and household contacts evaluated for active TB were assessed by sputum smear microscopy with Ziehl-Neelsen staining and culture on solid Lowenstein-Jensen medium. Initial DST was performed by using the proportion method on Lowenstein-Jensen medium; second-line DST was performed by using the proportion method on Middlebrook 7H11 agar. We shipped 100 µL of the lysate from suspensions of mycobacterial colonies harvested from Lowenstein-Jensen slants to Genoscreen (Institute Pasteur, Lille, France) for 24-loci MIRU-VNTR typing.

The standard threshold approach for classifying complex infections by using MIRU-VNTR data classifies patterns with >1 band (i.e., repeat copy number) at a single locus as clonal infections and patterns with >1 band at multiple loci as polyclonal infections (9). To better distinguish between clonal and polyclonal infections, we used an alternative method called ClassTR, which leverages additional information about differences in loci copy numbers and from other strains present in the population (8). In simulation studies, ClassTR more accurately distinguished between these 2 mechanisms of within-host diversity than did the threshold approach (8).

1These authors contributed equally to this article.
To understand whether our findings were robust to the classification approach used, we adopted ClassTR for our main analysis, but we also repeated all analyses with the threshold approach. We used univariable and multivariable multinomial logistic regression to identify baseline factors independently associated with having a clonal or a polyclonal infection, setting simple infection as the referent. Analysis was limited to complete cases. Co-linearity was assessed by calculating variance inflation factors, and p<0.05 was considered statistically significant. Co-linear variables were removed to produce the final multivariable model. Statistical analyses were conducted in R version 3.3 (http://www.R-project.org). Research ethics committees in Peru and Boston approved the study.

We analyzed results for 3,098 participants. Most participants were <35 years of age (64.8%) and male (61.9%); 108 (3.5%) were known to be HIV infected. Nearly a fifth (18.8%) of participants reported a prior history of TB, and 78 (2.5%) reported having received a course of isoniazid chemoprophylaxis. A total of 375 (12.1%) participants had MDR-TB, 288 (9.3%) had isoniazid or rifampin monoresistance, and 357 (11.5%) had other resistance patterns (predominantly streptomycin resistance). A total of 2,822 (91.1%) participants had simple infections and 3.7% had clonal infections.

Using ClassTR, we classified VNTR), and the remaining 276 (8.9%) had evidence of within-host heterogeneity. Using MIRU-VNTR, we classified 161 (5.2%) infections as polyclonal and 115 (3.7%) as clonal (Table 1).

Table 1. *Mycobacterium tuberculosis* resistance patterns among patients with pulmonary TB, Lima, Peru, September 2009–August 2012

<table>
<thead>
<tr>
<th>Resistance†</th>
<th>Simple, no. (%)</th>
<th>Clonal, no. (%)</th>
<th>Polyclonal, no. (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pansensitive</td>
<td>1,917 (67.9)</td>
<td>73 (63.5)</td>
<td>88 (54.7)</td>
</tr>
<tr>
<td>INH or RIF resistance</td>
<td>260 (9.2)</td>
<td>11 (9.6)</td>
<td>17 (10.6)</td>
</tr>
<tr>
<td>Multidrug</td>
<td>333 (11.8)</td>
<td>15 (13.0)</td>
<td>27 (16.8)</td>
</tr>
<tr>
<td>Other†</td>
<td>312 (11.1)</td>
<td>16 (13.9)</td>
<td>29 (18.0)</td>
</tr>
<tr>
<td>Total</td>
<td>2,822</td>
<td>115</td>
<td>161</td>
</tr>
</tbody>
</table>

*Results of multivariable regression analysis using classifier of tandem repeats method. aOR, adjusted odds ratio; INH, isoniazid; RIF, rifampin; TB, tuberculosis.

Table 2. Factors associated with clonal and polyclonal *Mycobacterium tuberculosis* infection among patients with pulmonary TB, Lima, Peru, September 2009–August 2012

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Clonal aOR (95% CI), n = 115</th>
<th>p value</th>
<th>Polyclonal aOR (95% CI), n = 161</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, y</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15–24</td>
<td>Referent</td>
<td>1.21 (0.75–1.96)</td>
<td>0.44</td>
<td>1.40 (0.93–2.11)</td>
</tr>
<tr>
<td>25–34</td>
<td></td>
<td>1.33 (0.79–2.23)</td>
<td>0.29</td>
<td>1.22 (0.77–1.95)</td>
</tr>
<tr>
<td>35–44</td>
<td></td>
<td>1.16 (0.64–2.11)</td>
<td>0.62</td>
<td>1.42 (0.87–2.31)</td>
</tr>
<tr>
<td>≥45</td>
<td></td>
<td>0.93 (0.63–1.38)</td>
<td>0.72</td>
<td>1.10 (0.78–1.55)</td>
</tr>
<tr>
<td>Male sex</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>Referent</td>
<td>0.82 (0.48–1.37)</td>
<td>0.45</td>
<td>1.27 (0.88–1.86)</td>
</tr>
<tr>
<td>Previous TB</td>
<td></td>
<td>1.51 (0.54–4.27)</td>
<td>0.44</td>
<td>1.84 (0.82–4.15)</td>
</tr>
<tr>
<td>Previous INH receipt</td>
<td></td>
<td>0.99 (0.35–2.78)</td>
<td>0.98</td>
<td>1.12 (0.50–2.49)</td>
</tr>
<tr>
<td>≥1 chronic disease</td>
<td></td>
<td>0.90 (0.55–1.46)</td>
<td>0.66</td>
<td>0.97 (0.64–1.46)</td>
</tr>
<tr>
<td>Hospitalized</td>
<td></td>
<td>1.01 (0.58–1.75)</td>
<td>0.97</td>
<td>0.98 (0.61–1.57)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Resistance pattern</th>
<th>Clonal aOR (95% CI), n = 115</th>
<th>p value</th>
<th>Polyclonal aOR (95% CI), n = 161</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>INH or RIF resistance</td>
<td>1.11 (0.58–2.13)</td>
<td>0.76</td>
<td>1.38 (0.81–2.37)</td>
<td>0.24</td>
</tr>
<tr>
<td>Multidrug resistance</td>
<td>1.24 (0.70–2.22)</td>
<td>0.46</td>
<td>1.66 (1.05–2.62)</td>
<td>0.03</td>
</tr>
<tr>
<td>Other†</td>
<td>1.34 (0.77–2.33)</td>
<td>0.31</td>
<td>1.97 (1.27–3.06)</td>
<td>0.002</td>
</tr>
</tbody>
</table>

*Results of multivariable regression analysis using classifier of tandem repeats method. aOR, adjusted odds ratio; INH, isoniazid; RIF, rifampin; TB, tuberculosis.
more than the increased risk that would accrue from multiple exposures.

A review of the literature on factors associated with within-host diversity revealed substantial variability between settings. Studies from Botswana and Taiwan found a higher prevalence of polyclonal infection among patients with MDR-TB (10,11); however, studies from Vietnam and KwaZulu-Natal (South Africa) did not find this association (12,13). It is possible that this association may be modified in the presence of HIV co-infection or that the ability to identify such an association is easier in areas where the prevalence of multidrug resistance is higher.

The main strengths of this study relate to the large prospective cohort of pulmonary TB patients evaluated in a study area with a population of 3.3 million persons. However, 30% of enrolled participants did not have culture-confirmed TB, precluding MIRU-VNTR analysis on all participants. Use of the MIRU-VNTR assay on cultured specimens to detect within-host heterogeneity was motivated by practical considerations. Because MIRU-VNTR typing is unable to identify all minority variants, and some diversity may be lost during culture (14), our categorization of infections into simple, clonal, and polyclonal may be subject to misclassification, which would be differential (i.e., complex infections are more likely to be misclassified as simple than the reverse) and could lead to bias. The use of a high number of MIRU-VNTR loci also reduces the likelihood of homoplasy. Furthermore, although the biological clock of the MIRU-VNTR marker seems to be relatively stable (recently estimated MIRU-VNTR mutation rate for TB is $2.70 \times 10^{-3}$ mutations/locus/year [15]), changes accruing in the marker could lead to misclassification of clonal strains as polyclonal strains; we used the ClassTR method in an attempt to minimize such misclassification.

We found complex infections attributable to multiple infection events to be associated with increased risk for MDR TB. This finding further emphasizes the value of efforts to mitigate the transmission of MDR TB.

R.R.N. was supported by a Scholar Award from the Harvard Center for AIDS Research (National Institutes of Health [NIH] National Institute of Allergy and Infectious Diseases 2P30AI060354-11) and an Imperial College Global Health Institutional Strategic Support Fund fellowship from the Wellcome Trust. C.X.S. was supported by awards T32MH020031 and P30MH062294 from the NIH National Institute of Mental Health. L.C. was supported by a Natural Sciences and Engineering Research Council of Canada Discovery Grant and a Sloan Foundation Fellowship. L.C. and T.C. received support from an award from the NIH National Institute of General Medical Sciences (U54GM088558). L.C., R.C., Z.Z., J.G., C.C., R.Y., L.L., M.C.B., M.B.M., T.C., and collection of all data presented were supported by NIH (U01AI057786, U19A1076217).

Dr. Nathavitharan is an infectious diseases physician and research fellow at Beth Israel Deaconess Medical Center and Harvard Medical School, in Boston, Massachusetts, USA. Her primary research interests include using novel diagnostic strategies to characterize and decrease TB transmission.

References


Address for correspondence: Ruvandhi R. Nathavitharana, Beth Israel Deaconess Medical Center–Infectious Diseases, 110 Francis St, Ste GB, Boston, MA 02215-5501, USA; email: mathavi@bidmc.harvard.edu

March 2015: Tuberculosis

- Regional Spread of Ebola Virus, West Africa, 2014
- Spillover of Mycobacterium bovis from Wildlife to Livestock, South Africa
- Prisons as Reservoir for Community Transmission of Tuberculosis, Brazil
- Polycystic Echinococcosis in Pacas, Amazon Region, Peru
- Spatiotemporal Analysis of Guaroa Virus Diversity, Evolution, and Spread in South America
- Red Deer as Maintenance Host for Bovine Tuberculosis, Alpine Region
- Noninvasive Test for Tuberculosis Detection among Primates
- Increased Risk for Multidrug-Resistant Tuberculosis in Migratory Workers, Armenia
- Endemic and Imported Measles Virus–Associated Outbreaks among Adults, Beijing, China, 2013
- Mycobacterium bovis Infection in Humans and Cats in Same Household, Texas, USA, 2012
- Reemergence of Murine Typhus in Galveston, Texas, USA, 2013
- Severe Fever with Thrombocytopenia Syndrome in Japan and Public Health Communication
- Novel Mutations in K13 Propeller Gene of Artemisinin-Resistant Plasmodium falciparum
- Comparison of Porcine Epidemic Diarrhea Viruses from Germany and the United States, 2014
- Buruli Ulcer in Traveler from Suriname, South America, to the Netherlands
- Moxifloxacin Prophylaxis Against MDR TB, New York, New York, USA
- Rapid Detection of ESBL-Producing Enterobacteriaceae in Blood Cultures
- Characteristics of Tuberculosis Cases that Started Outbreaks in the United States, 2002–2011
- Reassortant Highly Pathogenic Influenza A(H5N6) Virus in Laos
- Autochthonous Dengue Fever, Tokyo, Japan, 2014
- Treatment of Ebola Virus Infection with Antibodies from Reconvalescent Donors
- Tuberculosis Microepidemics among Dispersed Migrants, Birmingham, UK, 2004–2013

https://wwwnc.cdc.gov/eid/content/21/3/contents.htm
Polyclonal Pulmonary Tuberculosis Infections and Risk for Multidrug Resistance, Lima, Peru

Technical Appendix

Table 1. Results of univariable regression analysis of factors associated with clonal and polyclonal MTB infection using ClassTR classification approach

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Clonal OR N = 115 95% CI p value</th>
<th>Polyclonal OR N = 161 95% CI p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, y</td>
<td>Ref</td>
<td>Ref</td>
</tr>
<tr>
<td>15–24</td>
<td></td>
<td></td>
</tr>
<tr>
<td>25–34</td>
<td>1.18 0.73 1.90 0.50 1.44 0.96 2.15 0.08</td>
<td></td>
</tr>
<tr>
<td>35–44</td>
<td>1.11 0.62 2.00 0.72 1.48 0.92 2.39 0.11</td>
<td></td>
</tr>
<tr>
<td>45</td>
<td>1.23 0.75 2.03 0.41 1.23 0.79 1.91 0.37</td>
<td></td>
</tr>
<tr>
<td>Male sex</td>
<td>0.93 0.63 1.36 0.70 1.13 0.81 1.57 0.48</td>
<td></td>
</tr>
<tr>
<td>Previous TB</td>
<td>0.87 0.53 1.44 0.59 1.45 1.01 2.10 0.05</td>
<td></td>
</tr>
<tr>
<td>Previous INH</td>
<td>1.48 0.53 4.14 0.45 1.87 0.84 4.14 0.12</td>
<td></td>
</tr>
<tr>
<td>HIV-positive</td>
<td>1.01 0.37 2.80 0.98 1.28 0.58 2.80 0.54</td>
<td></td>
</tr>
<tr>
<td>≥1 Chronic disease</td>
<td>0.97 0.61 1.53 0.89 0.98 0.67 1.45 0.93</td>
<td></td>
</tr>
<tr>
<td>Hospitalized</td>
<td>1.03 0.60 1.76 0.92 1.01 0.64 1.60 0.97</td>
<td></td>
</tr>
<tr>
<td>Resistance pattern</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pan-sensitive</td>
<td>Ref</td>
<td>Ref</td>
</tr>
<tr>
<td>INH or RIF resistance</td>
<td>1.11 0.58 2.12 0.75 1.42 0.83 2.43 0.20</td>
<td></td>
</tr>
<tr>
<td>MDR</td>
<td>1.18 0.67 2.09 0.56 1.77 1.13 2.76 0.01</td>
<td></td>
</tr>
<tr>
<td>Other DR</td>
<td>1.35 0.77 2.34 0.29 2.03 1.31 3.13 0.002</td>
<td></td>
</tr>
</tbody>
</table>

Table 2. Resistance Patterns according to MTB Strain Type determined by threshold classification approach

<table>
<thead>
<tr>
<th>Resistance*</th>
<th>Simple N (%)</th>
<th>Clonal N (%)</th>
<th>Polyclonal N (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pan-sensitive</td>
<td>1917 (67.9)</td>
<td>112 (68.7)</td>
<td>49 (43.4)</td>
</tr>
<tr>
<td>INH or RIF resistance</td>
<td>260 (9.2)</td>
<td>17 (10.4)</td>
<td>11 (9.7)</td>
</tr>
<tr>
<td>MDR</td>
<td>333 (11.8)</td>
<td>11 (6.7)</td>
<td>31 (27.4)</td>
</tr>
<tr>
<td>Other</td>
<td>312 (11.1)</td>
<td>23 (14.1)</td>
<td>22 (19.5)</td>
</tr>
<tr>
<td>Total</td>
<td>2822</td>
<td>163</td>
<td>113</td>
</tr>
</tbody>
</table>

*Drug susceptibility testing was performed for the following drugs: rifampicin, isoniazid, streptomycin, ethambutol, and pyrazinamide.

Table 3. Results of multivariable regression analysis of factors associated with clonal and polyclonal MTB infection using threshold classification approach

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Clonal aOR N = 115 95% CI p value</th>
<th>Polyclonal aOR N = 161 95% CI p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, y</td>
<td>Ref</td>
<td>Ref</td>
</tr>
<tr>
<td>15–24</td>
<td></td>
<td></td>
</tr>
<tr>
<td>25–34</td>
<td>1.37 0.91 2.07 0.13 1.22 0.75 1.97 0.42</td>
<td></td>
</tr>
<tr>
<td>35–44</td>
<td>1.53 0.94 2.48 0.09 1.04 0.56 1.91 0.91</td>
<td></td>
</tr>
<tr>
<td>45</td>
<td>1.36 0.87 2.12 0.18 1.16 0.67 2.02 0.60</td>
<td></td>
</tr>
<tr>
<td>Male sex</td>
<td>0.98 0.70 1.36 0.88 1.13 0.75 1.71 0.56</td>
<td></td>
</tr>
<tr>
<td>Previous TB</td>
<td>0.72 0.46 1.15 0.17 1.63 1.06 2.50 0.03</td>
<td></td>
</tr>
<tr>
<td>Previous INH</td>
<td>1.13 0.40 3.18 0.81 2.48 1.08 5.72 0.03</td>
<td></td>
</tr>
<tr>
<td>HIV-Positive</td>
<td>0.67 0.24 1.86 0.44 1.67 0.73 3.81 0.22</td>
<td></td>
</tr>
<tr>
<td>≥1 Chronic disease</td>
<td>1.04 0.70 1.55 0.85 0.78 0.46 1.31 0.35</td>
<td></td>
</tr>
<tr>
<td>Hospitalized</td>
<td>1.09 0.69 1.72 0.71 0.85 0.47 1.52 0.58</td>
<td></td>
</tr>
<tr>
<td>Resistance pattern</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pan-sensitive</td>
<td>Ref</td>
<td>Ref</td>
</tr>
<tr>
<td>INH or RIF resistance</td>
<td>1.11 0.65 1.88 0.71 1.59 0.82 3.11 0.17</td>
<td></td>
</tr>
<tr>
<td>MDR</td>
<td>0.60 0.32 1.14 0.12 3.25 2.01 5.26 &lt;0.001</td>
<td></td>
</tr>
<tr>
<td>Other DR</td>
<td>1.25 0.78 1.99 0.35 2.70 1.61 4.55 &lt;0.001</td>
<td></td>
</tr>
</tbody>
</table>
Technical Appendix Table 4. Results of univariable regression analysis of factors associated with clonal and polyclonal MTB infection using threshold classification approach

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Clonal OR N = 115</th>
<th>95% CI</th>
<th>p value</th>
<th>Polyclonal OR N = 161</th>
<th>95% CI</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, y</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15–24</td>
<td>Ref</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>25–34</td>
<td>1.32</td>
<td>0.88</td>
<td>1.99</td>
<td>0.18</td>
<td>1.32</td>
<td>0.83</td>
</tr>
<tr>
<td>35–44</td>
<td>1.45</td>
<td>0.90</td>
<td>2.34</td>
<td>0.13</td>
<td>1.14</td>
<td>0.63</td>
</tr>
<tr>
<td>≥45</td>
<td>1.34</td>
<td>0.88</td>
<td>2.06</td>
<td>0.18</td>
<td>1.08</td>
<td>0.64</td>
</tr>
<tr>
<td>Male sex</td>
<td>0.93</td>
<td>0.68</td>
<td>1.29</td>
<td>0.67</td>
<td>1.22</td>
<td>0.82</td>
</tr>
<tr>
<td>Previous TB</td>
<td>0.72</td>
<td>0.46</td>
<td>1.13</td>
<td>0.16</td>
<td>2.06</td>
<td>1.37</td>
</tr>
<tr>
<td>Previous INH</td>
<td>1.03</td>
<td>0.37</td>
<td>2.87</td>
<td>0.95</td>
<td>2.72</td>
<td>1.22</td>
</tr>
<tr>
<td>HIV-Positive</td>
<td>0.71</td>
<td>0.26</td>
<td>1.95</td>
<td>0.50</td>
<td>1.86</td>
<td>0.84</td>
</tr>
<tr>
<td>≥1 Chronic disease</td>
<td>1.12</td>
<td>0.77</td>
<td>1.62</td>
<td>0.56</td>
<td>0.79</td>
<td>0.48</td>
</tr>
<tr>
<td>Hospitalized</td>
<td>1.10</td>
<td>0.70</td>
<td>1.72</td>
<td>0.68</td>
<td>0.90</td>
<td>0.51</td>
</tr>
<tr>
<td>Resistance pattern</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pan-sensitive</td>
<td>Ref</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>INH or RIF resistance</td>
<td>1.12</td>
<td>0.66</td>
<td>1.89</td>
<td>0.68</td>
<td>1.66</td>
<td>0.85</td>
</tr>
<tr>
<td>MDR</td>
<td>0.57</td>
<td>0.30</td>
<td>1.06</td>
<td>0.08</td>
<td>3.64</td>
<td>2.29</td>
</tr>
<tr>
<td>Other DR</td>
<td>1.26</td>
<td>0.79</td>
<td>2.01</td>
<td>0.33</td>
<td>2.76</td>
<td>1.65</td>
</tr>
</tbody>
</table>